Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 while maintaining a Buy rating on the shares. Although the firm is ...

On May 27, Citizens JMP lowered the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform rating on the shares. The notable price target decrease ...

Fintel reports that on May 28, 2025, B of A Securities downgraded their outlook for Prothena (NasdaqGS:PRTA) from Neutral to Underperform. Analyst Price Forecast Suggests 1,045.01% Upside As of ...